Point-of-care Assay Development
Point-of-care Assay Development - Related Videos
11:12
Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
0 Views •
Cited by 1 •
2017
We describe a method to quantify the aggregation of misfolded proteins. Our protocol details lentiviral induced stable cell line generation, automated confocal imaging, and image analysis of protein aggregates. As an illustrative application, we studied the effect of small molecules in promoting SOD1 aggregation in a time- and dose-dependent manner.
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
0 Views •
2012
Demonstration of a rapid quantitative assay of the inhibition of blood coagulation by the low-molecular-weight-heparin, enoxaparin. The contribution of enoxaparin is assessed by removing its influence through digestion with heparinase. A fuller description of the assay is detailed in our published paper.1 The assay still requires clinical confirmation.
07:40
Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
0 Views •
2022
This protocol describes the generation of a skin-fascia explant termed "SCar like tissue in A Dish" or SCAD. This model allows unprecedented visualization of single fibroblasts during scar formation.
07:50
Assay Development for High-Throughput Drug Screening Against Mycobacteria
0 Views •
2024
This study developed an assay for high-throughput screening against Mycobacterium abscessus with a recently created double reporter strain, using fluorescence and luminescence to assess bacterial viability quickly. This protocol will be relevant for researchers aiming to screen new drugs against this drug-resistant bacteria.
01:21
Interdisciplinary Care: The Health Care Team-I
0 Views •
2023
An interdisciplinary team includes many healthcare professionals working together and utilizing their skills, knowledge, and expertise to provide holistic and quality patient care. Physicians The physician's primary responsibility is to diagnose illness and direct the medical or surgical treatment of the condition. The authority to admit patients to a healthcare agency or institution and practice care within that setting is granted to physicians by the healthcare agency or institution itself.
FAQs
Successful designs treat these elements as one connected workflow rather than independent parts. Recognition must capture or identify the intended target, sample preparation must make that target accessible, signal generation must convert the interaction into a measurable response, and the portable readout must interpret it within the available time and equipment limits. This integration determines whether the assay produces actionable results.
Analytical sensitivity, specificity, stability, and usability are central performance characteristics. Sensitivity affects detection of the intended target, whereas specificity helps distinguish it from other material in the sample. Stability supports reliable operation over practical conditions, and usability determines whether the workflow can be performed with limited equipment, small sample volumes, and short processing times.
Small sample volumes limit the amount of target available for detection, while short processing times constrain preparation, recognition, signal development, and result interpretation. Developers therefore balance rapid operation against the need for adequate analytical sensitivity and specificity. These constraints are especially important when results must guide screening, treatment decisions, or monitoring without relying on a centralized laboratory.
The main difference is where and under what practical constraints testing occurs. A point-of-care format brings the workflow near the patient or sample source and emphasizes portable equipment, limited materials, small volumes, and rapid turnaround. Centralized workflows are not the focus of this approach; instead, decentralization can support timely decisions and studies in settings where laboratory access is limited.
Development begins by selecting the biological target and recognition approach, then linking sample preparation to signal generation and a portable readout. The integrated workflow is optimized for small sample volumes, limited equipment, and short processing times. Developers then assess sensitivity, specificity, stability, and usability to determine whether the resulting test can provide reliable, actionable information in its intended setting.
Point-of-care assay development can address nucleic acids, proteins, metabolites, or whole cells. The target class shapes the recognition strategy, sample preparation needs, signal generation, and readout design. This range allows the same general development framework to support different biological questions, from detecting molecular material to identifying cellular components in clinical, environmental, or research samples.
They are particularly valuable when rapid, localized information can change an immediate decision or support decentralized sampling. Applications include disease screening, treatment decisions, outbreak monitoring, and research studies conducted outside centralized laboratory settings. Their usefulness depends on matching the assay's target and performance characteristics to the biological question, sample type, and operational conditions of the application.
These assays can provide actionable detection results from clinical, environmental, and research samples, including information about nucleic acids, proteins, metabolites, or whole cells. Rapid turnaround may support timely disease screening, treatment decisions, and outbreak monitoring. In decentralized studies, portable testing can also extend measurements closer to the patient or sample source while preserving attention to analytical performance and usability.